Biotechnology - Pharmaceutical, Immunologicals


Popular Filters

Novartis enters into a collaboration for Il-17 inhibitor


US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Teijin and Amgen join forces on autoimmune disease research


Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

Merck Serono sets up new platform for cancer therapies innovation


Merck Serono, the biopharmaceutical division of Germany's Merck KGaA (MRK: DE) says it has created a…

BiotechnologyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData


Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Additional indications in Japan for Roche's Avastin and Astellas' Prograf


Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Baxter and Halozyme's HyQvia approved in European Union


USA-based Baxter International (NYSE: BAX) and Halozyme Therapeutics (Nasdaq: HALO) say that the European…

BaxterBiotechnologyEuropeHalozyme TherapeuticsHyQviaImmunologicalsPharmaceuticalRegulation

US FDA accepts Merck & Co's BLA ragweed pollen allergy immunotherapy


US pharma giant Merck & Co (NYSE: MRK) revealed yesterday (May 8) that the Biologics License Application…

Alk-AbelloBiotechnologyImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

Sanofi and Transgene collaborate on immunotherapy treatments; NAS designation of Aubagio disputed


Drug major Sanofi (Euronext: SAN) and fellow France-based biotech firm Transgene SA (NYSE-Euronext: TNG)…


Positive NICE news for GSK's Revolade and InterMune's Esbriet


UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

FDA advisory gives negative opinion on Hemispherx' Ampligen


The Arthritis Advisory Committee (AAC) of the US Food and Drug Administration last week voted against…

AmpligenBiotechnologyHemispherx BioPharmaImmunologicalsNorth AmericaPharmaceuticalRegulation

Sanofi inks up to $900 million allergy pact with Selecta Biosciences


US clinical-stage biopharma company Selecta Biosciences revealed this morning that it has entered into…

BiotechnologyImmunologicalsLicensingPharmaceuticalResearchSanofiSelecta BiosciencesVaccines

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S


Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi


As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi…

BiotechnologyChondrogenGenzymeImmunologicalsInflammatory diseasesLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Abbott/Eisai's Humira has emerged as leading psoriasis agent


For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

Barriers to overcome in lupus drug development


It has taken the lupus research community over 50 years to produce a new therapy. Although it is now…

Anthera PharmaceuticalsBenlystaBiotechnologyblisibimodGlaxoSmithKlineImmunologicalsPharmaceuticalResearch

GlaxoSmithKline links with Japan's Chiome on MAbs


UK pharma giant GlaxoSmithKline group (LSE: GSK) and Tokyo, Japan-based biotech-venture company Chiome…

BiotechnologyChiome BioscienceGlaxoSmithKlineImmunologicalsLicensingOncologyPharmaceuticalResearch

Ablynx extends Nanobody deal with Boehringer


Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Back to top